Insulet (NASDAQ:PODD) Announces Earnings Results, Beats Expectations By $0.40 EPS

Posted by Francis Steltz on Nov 6th, 2026

Insulet (NASDAQ:PODD – Get Free Report) announced its earnings results on Wednesday. The medical instruments supplier reported $1.99 EPS for the quarter, topping the consensus estimate of $1.59 by $0.40, FiscalAI reports. Insulet had a net margin of 13.44% and a return on equity of 31.76%. The firm had revenue of $842.00 million for the quarter, compared to the consensus estimate of $832.63 million. During the same period last year, the company posted $1.24 EPS. The business’s quarterly revenue was up 19.2% on a year-over-year basis.

Here are the key takeaways from Insulet’s conference call:

Third-quarter revenue rose 19.6% in constant currency to $842 million, supported by more than 20% growth in the global customer base. Adjusted operating margin expanded 490 basis points, and adjusted EPS increased 60% year over year.
Insulet raised its 2026 outlook to the high end of its prior range, expecting 21%–22% constant-currency revenue growth and more than 30% adjusted EPS growth. It also expects approximately 150 basis points of adjusted operating margin expansion.
Management expects 2027 revenue growth to be modestly below its prior mid-teens framework, with U.S. growth toward the lower end of its earlier range and international growth moderating meaningfully. The company cited tougher comparisons, less international price-mix benefit, new competition, and limited near-term contributions from launches.
Insulet reported modest improvement in type 2 customer retention after changes to sampling, onboarding, sales incentives, and customer support. Its Omnipod Discover platform has been adopted by more than 35,000 users and 5,000 clinicians, though management said the impact of these efforts will build over time.
The board approved a $1 billion increase to the share repurchase authorization, with $400 million planned for repurchases in the fourth quarter using cash on hand.

Insulet Stock Performance

Shares of PODD traded down $12.48 during midday trading on Friday, reaching $143.64. 533,289 shares of the stock were exchanged, compared to its average volume of 1,393,656. Insulet has a twelve month low of $126.40 and a twelve month high of $354.88. The company has a quick ratio of 1.83, a current ratio of 2.51 and a debt-to-equity ratio of 0.60. The company has a market cap of $9.96 billion, a P/E ratio of 23.37, a PEG ratio of 1.25 and a beta of 1.06. The stock’s 50 day simple moving average is $141.91 and its 200 day simple moving average is $177.34.

Key Headlines Impacting Insulet

Here are the key news stories impacting Insulet this week:

Positive Sentiment: Third-quarter performance was strong: Insulet reported $842 million in revenue, up 19.2% year over year, and adjusted EPS of $1.99, beating analyst estimates. The company also announced a $1 billion share repurchase program. Insulet CEO discusses growth and competition
Positive Sentiment: Several firms lifted their price targets. RBC raised its target to $180 and kept an Outperform rating; Bernstein raised its target to $200 and also rated the shares Outperform. RBC raises Insulet price target
Neutral Sentiment: Other target increases came with Neutral or Market Perform ratings, suggesting analysts see potential recovery but remain measured in their outlook. RBC also described the valuation as attractive while noting a more conservative 2027 outlook. RBC on Insulet valuation and outlook
Negative Sentiment: The main concern is slower growth expected in 2027. Insulet’s CEO also expects competitors to take some Omnipod market share, raising questions about the pace of future growth despite the latest-quarter beat. Insulet CEO discusses growth and competition

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Truist Financial downgraded shares of Insulet from a “buy” rating to a “hold” rating and decreased their target price for the company from $210.00 to $153.00 in a research report on Wednesday, August 5th. Raymond James Financial reissued an “outperform” rating and set a $180.00 price target on shares of Insulet in a research report on Thursday, August 6th. Royal Bank Of Canada boosted their price target on shares of Insulet from $160.00 to $180.00 and gave the stock an “outperform” rating in a research report on Thursday. Canaccord Genuity Group reduced their price objective on shares of Insulet from $249.00 to $179.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $200.00 price objective on shares of Insulet in a report on Wednesday. Thirteen investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $192.96.

Get Our Latest Analysis on Insulet

About Insulet

(Get Free Report)

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.